ArticleEClinicalMedicine2025

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.

Niels A D Guchelaar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.